BVM Capital backs MicroBiome Therapeutics

MicroBiome Therapeutics has closed $1.3 million in bridge financing. Existing investor BVM Capital led the round with participation from MBT’s other existing investors. Headquartered in Broomfield, Colorado, MicroBiome Therapeutics is a clinical stage biotechnology company that develops pharmaceutical and medical food products.

PRESS RELEASE

Broomfield, CO – December 16, 2013 – MicroBiome Therapeutics™ LLC, (MBT) today announced completion of a $1.3 million bridge financing from current investors. It is intended to support completion of the company’s two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.
“We welcome our investors’ continuing support as we wrap up our pilot studies of NM504 and prepare for the next phase of clinical trials,” noted Steve Orndorff, CEO of Microbiome Therapeutics. “Growing evidence supports a role for the gut microbiome in a range of disorders, and interest in the therapeutic potential of microbiome modulators is soaring. These additional funds will enable us to complete our ongoing studies and prepare for our next set of clinical trials. We expect to report results from the current studies soon, prior to the launch of a significant Series B financing during 2014.”
NM504 is being studied in two placebo-controlled, double-blinded, proof of concept trials. The first is assessing its ability to alter the gastrointestinal (GI) microbiome to enhance insulin sensitivity and fasting blood glucose levels in prediabetic individuals. The second is testing the utility of NM504 in combination with metformin in diabetes patients with adverse GI effects. NM504 has previously demonstrated the potential to mitigate these adverse effects.
MBT is developing microbiome modulators that alter bacterial populations and their environment in the GI tract to address serious health conditions. The company’s microbiome modulators are designed to act on multiple factors in the GI environment, augmenting the growth of targeted desirable bacterial strains and discouraging the growth of others. NM504 is formulated to promote microbiome shifts that positively affect metabolism and weight.
Separately, the company announced that it will be presenting at Biotech Showcase™ 2014 in San Francisco on January 13, 2014 at 9:15am PT. For more information, visit ebdgroup.com/bts/index.php
About MicroBiome Therapeutics™
MicroBiome Therapeutics LLC (MBT), is a clinical stage biotechnology company developing pharmaceutical and medical food products that aim to improve health status by interacting with and altering the human microbiome. MBT is developing evidence-based microbiome modulators to address serious health conditions. Lead product NM504 is being tested in clinical trials for the management of insulin sensitivity and blood glucose levels and as an adjunct to metformin in patients with prediabetes and type 2 diabetes. For more information, visit www.mbiome.com.

Related Posts

Leave a Reply

PEHUB Community

Join the 12494 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget

Groups